首页/数据集/Supplemental Material: Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol

Supplemental Material: Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol

Dryad2014-01-01 更新2026-04-13 收录

COPD药物治疗

间接比较分析

数据链接：

http://datadryad.org/resource/doi:10.5061/dryad.88rb5/1 数据链接链接失效反馈

官方服务：

资源简介：

Indirect Comparison of Olodaterol and Indacaterol. Supplemental Material: Roskell et al. Int J Chron Obstruct Pulmon Dis. 2014.

应用场景：

创建时间：

2014-01-01

COPD药物治疗

支气管上皮细胞基因表达

The Differential Effects of Inhaled Symbicort and AdvaiR on Lung Microbiota (DISARM) study aimed to determine the effects of inhaled corticosteroids (ICS) on the lung microbiome. The full trial protoc

NIAID Data Ecosystem100

Dataset from Efficacy {FEV1, COPD Exacerbations & HRQoL} & Safety of 5mcg Tiotropium Respimat in COPD

COPD药物治疗

慢性呼吸系统疾病管理

The objective of the study is to evaluate the long-term (one year) efficacy and safety of tiotropium delivered by the Respimat inhaler in patients with COPD. Specifically, the study will examine the e

NIAID Data Ecosystem40

A Randomized, Double-blind, Double-Dummy, Comparative Clinical Trial of 12-Week Courses of Salmeterol Xinafoate Versus Ipratropium Bromide Versus Placebo (PRN Ventolin) in Subjects With Chronic Obstructive Pulmonary Disease

COPD药物治疗

临床疗效比较

Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promot

DataCite Commons2024-12-02 更新10

Efficacy Results of Indacaterol by Comparison Type for SGRQ, TDI and BODE index.

COPD药物治疗

临床指标分析

? representing a 1.23 fold increase; # representing a 1.21 fold increase.

NIAID Data Ecosystem40

Dataset from A 12 Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy of Umeclidinium/Vilanterol 62.5/25mcg in Subjects With COPD

COPD药物治疗

吸入药物临床试验

This study is a 12-week, multicenter, randomized, double blind, parallel group, placebo-controlled study. The purpose of this study is to replicate the therapeutic benefit of UMEC/VI 62.5/25 microgram

NIAID Data Ecosystem10

Supplemental Material: Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol

资源简介：

相关数据集